DS-6000 Suggests Early Clinical Activity in ... - Daiichi Sankyo US
网页2022年6月7日 · Daiichi Sankyo (TSE: 4568) and Sarah Cannon Research Institute (Sarah Cannon) announced that initial results from the first-in-human phase 1 study of DS-6000, a CDH6 directed DXd antibody drug conjugate (ADC), suggest early clinical activity in patients with advanced ovarian cancer or renal cell carcinoma with disease progression following ...
Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 …
网页2021年2月3日 · Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-6000 is the sixth ADC in the Daiichi Sankyo oncology pipeline to enter clinical development. DS-6000 is comprised of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via …
网页ds-6000 是一款潜在成为同类首创的在研靶向cdh6 的抗体偶联药物，也是 第一三共肿瘤临床管线的五大ADC 药物之一。 DS-6000 采用第一三共专有的
网页2022年6月7日 · DS-6000 Suggests Early Clinical Activity in Patients with Advanced Ovarian Cancer or Renal Cell Carcinoma. Initial dose escalation results from first-in-human phase 1 trial of DS-6000, Daiichi Sankyo’s fifth DXd ADC in clinical development, featured in oral presentation at ASCO.
网页2022年5月23日 · First ever preliminary phase 1 results of DS-6000 in patients with advanced ovarian cancer and renal cell carcinoma also will be highlighted. DS-6000 is a potential first-in-class CDH6 directed ADC and the fifth DXd ADC from Daiichi Sankyo’s pipeline to report encouraging early clinical data.
Novel CDH6-Targeted ADC DS-6000 Enters the Pipeline in RCC …
网页2021年2月23日 · The first patient in a first-in-human phase 1 study (NCT04707248) has been dosed with DS-6000, a novel CDH6-directed antibody-drug conjugate (ADC), according to a press release from Daiichi...
抗体薬物複合体DS-6000の切除不能な腎細胞がんと卵巣がん患者 …
网页2021年2月3日 · 第一三共株式会社（本社：東京都中央区、以下「当社」）は、切除不能な腎細胞がんと卵巣がん患者を対象としたds-6000（cdh6を標的とした抗体薬物複合体（adc） *1 、以下「本剤」）の第1相臨床試験（以下「本試験」）において、最初の患者への投与を開始し ...
Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 …
网页2021年2月2日 · DS-6000 is a potential first-in-class CDH6 directed antibody drug conjugate (ADC). Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-6000 is the sixth ADC in the Daiichi...
网页2023年9月10日 · DS-6000), a CDH6 directed ADC, and DS-3939, a TA-MUC1 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology to target and deliver a cytotoxic payload inside cancer cells that express a specific cell surface antigen, each ADC consists of a
Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 …
网页2021年2月2日 · Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-6000 is the sixth ADC in the Daiichi Sankyo oncology pipeline to enter clinical development. DS-6000 is comprised of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via …